Intellia to advance CRISPR treatment for sickle cell

By The Science Advisory Board staff writers

November 11, 2020 -- Intellia Therapeutics has received a grant from the Bill & Melinda Gates Foundation to research in vivo sickle cell disease treatments using its CRISPR/Cas9 genome editing technology.

The funding will advance Intellia's preclinical validation of in vivo hematopoietic stem cells genome editing using the company's proprietary nonviral delivery systems and CRISPR/Cas9 technology to potentially cure sickle cell disease. The company's in vivo platform technology delivers CRISPR/Cas9 intravenously, which avoids the need for bone marrow transplantation surgery.

The funding is part of a broad program by the Gates Foundation to accelerate the advancement of safe, effective and durable gene-based cures in developing countries within the next seven to 10 years.

If you like this content, please share it with a colleague!

Related Reading

Survey queries informed consent for genome editing clinical trials
A new survey asked sickle cell disease patients, their parents, and physicians about what they want and need to know about genome editing in order to...

Modified CRISPR system aims to improve therapies for HIV, sickle cell disease
Researchers from City of Hope have improved the CRISPR-Cas9 system through novel sequence changes to the trans-activating RNA (tracrRNA). The improved...

NIH Invests $100 million in cures for sickle cell disease and HIV
The National Institutes of Health (HIH) announced that it plans to invest at least $100 million over the next four years towards developing affordable,...

Forward-oriented gene therapy improves treatment for sickle cell disease
Researchers at the National Institutes of Health (NIH) have developed a new and improved viral vector that is up to 10 times more efficient at incorporating...